A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

Type of Cancer
Skin and Soft Tissue

Sponsor
Merck

Protocol Number
MK-3475-629

To Learn More Call
(201)-510-0950